PMC:7600245 / 8066-8205 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T47","span":{"begin":81,"end":84},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T48","span":{"begin":110,"end":118},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":" parenterally administered drug is being developed by Gilead Sciences, U.S., and has broad-spectrum antiviral activity [26]. It was first s"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T61","span":{"begin":27,"end":31},"obj":"Chemical"},{"id":"T62","span":{"begin":100,"end":109},"obj":"Chemical"}],"attributes":[{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":" parenterally administered drug is being developed by Gilead Sciences, U.S., and has broad-spectrum antiviral activity [26]. It was first s"}